| Budget Amount *help |
¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
Fiscal Year 2014: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2013: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2012: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
Oncolytic viruses are promising therapeutic agents for cancer and are currently under clinical investigation. The virotherapy is novel strategy that viruses infect and replicate within tumor cells, directly lysing and killing them.
In this study, we have developed that microRNA (miRNA) regulation enables tumor-specific viral replication by altering the expression of a targeted viral gene of an attenuated vaccinia virus vaccine strain. We used miRNA-based gene regulation to suppress B5R expression through let-7, a miRNA that plays important roles in cancer stem cells through the downregulation of let-7 expression. The miRNA-regulated vaccinia virus (MDVV) achieved efficient viral replication and oncolysis in cancer cells, but elimination of unwanted replication and associated toxicity in normal cells in vivo. Furthermore, the MDVV armed with IL-12 enhanced its anti-tumor effects.
|
